Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China

重症肌无力 医学 回顾性队列研究 发病年龄 内科学 儿科 弱点 人口
作者
Yufan Zhou,Jialin Chen,Zunbo Li,Song Tan,Chong Yan,Sushan Luo,Lei Zhou,Jie Song,Xiao Huan,Ying Wang,Chongbo Zhao,Wenshuang Zeng,Jianying Xi
出处
期刊:Frontiers in Neurology [Frontiers Media]
卷期号:13
标识
DOI:10.3389/fneur.2022.879261
摘要

Introduction Antibodies to MuSK identify a rare subtype of myasthenia gravis (MuSK-MG). In western countries, the onset age of MuSK-MG peaks in the late 30's while it is unknown in Chinese population. Methods In this retrospective multicenter study, we screened 69 MuSK-MG patients from 2042 MG patients in five tertiary referral centers in China from October 2016 to October 2021 and summarized the clinical features and treatment outcomes. Then we subgrouped the patients into early-onset (<50 years old), late-onset (50–64 years old), and very-late-onset (≥65 years old) MG and compared the differences in weakness distribution, disease progression and treatment outcomes among three subgroups. Results The patients with MuSK-MG were female-dominant (55/69) and their mean age at onset was 44.70 ± 15.84 years old, with a broad range of 17–81 years old. At disease onset, 29/69 patients were classified as MGFA Type IIb and the frequency of bulbar and extraocular involvement was 53.6 and 69.6%, respectively. There was no difference in weakness distribution. Compared with early-onset MuSK-MG, very-late-onset patients had a higher proportion of limb muscle involvement (12/15 vs.16/40, p = 0.022) 3 months after onset. Six months after onset, more patients with bulbar (14/15 vs. 26/39, p = 0.044) and respiratory involvement (6/15 vs. 0/13, p = 0.013) were seen in very-late-onset than in late-onset subgroup. The very-late-onset subgroup had the highest frequency of limb weakness (86.7%, p < 0.001). One year after onset, very-late-onset patients demonstrated a higher frequency of respiratory involvement than early-onset patients (4/12 vs. 2/35, p = 0.036). 39/64 patients reached MSE. Among 46 patients who received rituximab, very-late-onset patients started earlier than late-onset patients [6 (5.5–7.5) vs. 18 (12–65) months, p = 0.039], but no difference in the time and rate to achieving MSE was identified. Conclusion MuSK-MG patients usually manifested as acute onset and predominant bulbar and respiratory involvement with female dominance. Very-late-onset patients displayed an early involvement of limb, bulbar and respiratory muscles in the disease course, which might prompt their earlier use of rituximab. The majority MuSK-MG patients can benefit from rituximab treatment regardless of age at onset.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kaikaifilu完成签到 ,获得积分10
刚刚
叶落风行发布了新的文献求助30
刚刚
卡卡完成签到,获得积分10
刚刚
MCFCSH发布了新的文献求助10
刚刚
可爱的函函的应助被yuuu采纳,获得10
1秒前
whhhhhh发布了新的文献求助20
1秒前
Pepsi完成签到,获得积分10
1秒前
1秒前
章鱼哥完成签到,获得积分10
2秒前
ljj完成签到,获得积分10
2秒前
2秒前
王的故郷完成签到,获得积分10
2秒前
mimi完成签到,获得积分10
3秒前
3秒前
无字诉题发布了新的文献求助10
3秒前
酷波er的应助被ZM采纳,获得10
3秒前
4秒前
咸柴完成签到,获得积分10
4秒前
4秒前
4秒前
小刘完成签到,获得积分10
4秒前
yun完成签到,获得积分10
5秒前
两个小王完成签到,获得积分10
5秒前
Blessing完成签到 ,获得积分10
5秒前
dycq完成签到 ,获得积分10
6秒前
蒋瑞轩发布了新的文献求助10
6秒前
务实寒天完成签到,获得积分10
6秒前
quhayley发布了新的文献求助10
6秒前
valentin完成签到,获得积分10
6秒前
无花果的应助被靓靓鱼采纳,获得10
6秒前
wsy完成签到,获得积分10
6秒前
maple完成签到,获得积分10
7秒前
7秒前
Xi完成签到,获得积分10
7秒前
zbearupz完成签到,获得积分10
7秒前
华仔的应助被郭益通采纳,获得10
8秒前
荷序完成签到,获得积分20
8秒前
8秒前
Xxiinp发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105